老年危重病患者早期胰岛素强化治疗对预后的影响

目的 探讨早期胰岛素强化治疗对老年危重病患者预后的影响,研究其对老年危重病患者脏器的保护作用.方法 选择76例老年(＞65岁)危重病患者,分为胰岛素强化治疗组和对照组,分别给予胰岛素强化治疗和常规治疗,并记录反映脏器功能的生化指标和预后主要指标.结果 胰岛素强化治疗实施的安全性良好.强化治疗严格控制血糖后,心功能、肝功能、肾功能不全发生率显著下降,两组患者死亡率、院内感染发生率比较差异有统计学意义.结论 对于老年危重病患者早期胰岛素强化治疗能更有效、更及时地控制血糖,并显著改善临床疗效.     

Solid dispersion of rutaecarpine improved its antihypertensive effect in spontaneously hypertensive rats

It was reported previously that rutaecarpine produced a hypotensive effect in phenol‐induced and 2‐kidney, 1‐clip hypertensive rats. However, the same dose of crude rutaecarpine did not produce significant hypotensive effects when applied to spontaneously hypertensive rats (SHR). In the present study, a different dose of rutaecarpine solid dispersion was administered intragastrically to SHR. The systolic blood pressure was monitored by the tail‐cuff method with an electro‐sphygmomanometer. The plasma concentration of rutaecarpine, calcitonin gene‐related peptide (CGRP) and the mRNA levels of CGRP in dorsal root ganglion were determined. The results showed that administration of the solid dispersion significantly increased the blood concentration of rutaecarpine, accompanied by significant hypotensive effects in SHR in a dose‐dependent manner. The levels of plasma CGRP were also elevated significantly, concomitantly with the increased mRNA levels in the dorsal root ganglion in a dose‐dependent manner. It was concluded that a change of the dosage from the crude drug to solid dispersion could improve significantly the efficiency of rutaecarpine absorption and increase its plasma concentration. The anti‐hypertensive effect exerted by rutaecarpine solid dispersion in SHR is mediated by CGRP. Copyright © 2008 John Wiley & Sons, Ltd.     

基于差异分析的隐蔽恶意代码检测

隐蔽性恶意程序Rootkit通过篡改系统内核代码与指令,导致操作系统返回虚假的关键系统信息,从而逃避管理员和主机型安全工具的检查.通过分析Rootkit技术的实现原理,包括进程、TCP端口、注册表和文件的隐藏技术,提出了基于差异分析的隐藏行为检测技术.该技术将可信任的系统信息与不可信任的系统信息进行比较,从而获得被隐藏的信息.最终实现了相应的原型系统.与特征码扫描法相比,该检测方法检测在未知和变形Rootkit方面具有明显优势.     

火(鍉)针速烙刺法治疗慢性咽炎

火(鍉)针疗法是用特制的(鍉)针烧后烙刺,运用该法治疗慢性咽炎,疗效显著,价格低廉,且无痛苦无副作用,是对中西医都不能根治的慢性咽炎的理想疗法.     

口服前药研究：机遇与挑战

前药研究是提高生物药剂学分类系统中第III和IV类药物口服吸收的有效途径之一。本文综述了近年来口服前药研究的进展，主要包括经典前药设计和靶向前药设计。经典前药设计重在改善母体药物的油水分配系数或减少药物的代谢。靶向前药设计重在主动利用胃肠道的生理特性靶向组织、酶及肠内流转运器，其中靶向小肠内流转运器-肽类转运器的口服前药成为目前研究的热点。前药研究还面临选题，设计和体内研究等方面的挑战。     

重组人促红细胞生成素改善老年慢性心力衰竭患者的心功能

目的:探讨重组人促红细胞生成素(rhEpo)改善老年慢性心力衰竭(CHF)患者心功能的作用.方法:选择慢性CHF患者66例,随机分为2组,对照组(30例)给予洋地黄制剂、利尿剂、血管扩张剂、血管紧张素转换酶抑制剂(ACEI)或β受体阻滞荆等常规药物;治疗组(36例)在常规药物治疗基础上加用rhEpo(2000 u,2～3次/周x24周)治疗.结果:rhEpo治疗组心功能改善的临床显效率(61.1%)和总有效率(88.8%)均较对照组(40%和53.3%)显著提高(P<0.01),且无明显的不良反应出现.治疗后与治疗前比较血红蛋白浓度显著增高,左室射血分数、左室舒张末期内径、左室舒张末容积、左室收缩末容积均有显著改善(P<0.01),治疗组与对照组比较差异有极显著性(P<().01).治疗前贫血程度与左室射血分数呈显著正相关(P相似文献   

青海马鹿肉营养及活性物质分析

<正>青海马鹿是我国马鹿的重要类群(Cervus elaphus linnaeus),分布于祁连山脉,食性较广,易饲养,抗病力强,体型较大,肉茸兼用,肉质细嫩鲜美,产茸量高。鹿肉、茸含能够提高人体代谢强度和抵抗力的强壮滋补物质,历来被人们认为是健身滋补的佳品[1]。本研究对青海马鹿肉的营养及活性物质进行了测定分析,为保护性开发利用提供科学资料。     

Identification of a novel S-superfamily conotoxin from vermivorous Conus caracteristicus

Conotoxins have been classified into several different superfamilies based on the highly conserved signal peptide sequences of their precursors. However, little is known about the five disulfide bonds containing S-superfamily conotoxins. Only two S-superfamily conotoxins have been identified but their cDNAs are not reported. In this work, we identified a novel S-superfamily conotoxin ca8a from vermivorous Conus caracteristicus. Its sequence shares no homology with those of two other previously reported toxins of the same superfamily, but they have the same cysteine framework, in particular the CX(3)CXC-CXC-CXCXC pattern at the C-terminal part. This implies that these toxins might have the same spatial scaffold, but different local conformation or residue side chains may be the cause of their different biological functions. Furthermore, the cDNA of ca8a was cloned with the RACE method. ca8a has a signal peptide sequence different from those of other conotoxins. This gives a defining feature of S-superfamily conotoxins and led to the cloning of more S-superfamily conotoxins from cone snails of different prey types, which indicates that S-superfamily conotoxins widely exist. These results will certainly enrich our understanding of the highly diversified S-superfamily conotoxins.     

18F‐fluorodeoxyglucose positron emission tomography imaging in brain tumours: The Western Australia positron emission tomography/cyclotron service experience

¹⁸F‐fluorodeoxyglucose positron emission tomography (FDG‐PET) scans in the first 49 patients referred with either possible brain tumour or brain tumour recurrence were reviewed. FDG‐PET imaging was reported with reference to anatomical imaging. Based on the report the FDG study was classified as either positive or negative for the presence of tumour. Thirty‐eight cases were included in the analysis, 21 having pathological data and 17 with diagnostic clinical follow up. Eleven were excluded, as they had inadequate follow‐up data. Of the 21 cases with pathology, 18 were shown to have tumour. In this group there were five false‐negative scans and two false‐positive PET scans. Seventeen cases were assessed by clinical follow up, nine were considered to have been tumour. There were two false negatives with one false positive. The overall sensitivity, specificity and positive and negative predictive values were 74, 73, 87 and 53% respectively. This is similar to figures previously quoted in published work. Despite relatively limited numbers, the utility of FDG PET imaging in our hands is similar to published reports. With a positive predictive value of 87%, a positive FDG study indicates a high likelihood that there is brain tumour present. A negative study does not exclude the presence of tumour.